METASTATIC UROTHELIAL CARCINOMA

This study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…

This early-stage trial is testing the safety and best dose of a three-drug combination for patients with advanced bladder cancer that has spread or cannot be removed by surgery. The treatment combines two immunotherapy drugs that help the immune system fight cancer with a third d…

This study is testing if adding a common, low-cost blood pressure medication called propranolol to standard immunotherapy helps people with advanced bladder cancer. Six participants will receive either immunotherapy alone or immunotherapy plus propranolol. The main goal is to see…

This study is for people with advanced bladder cancer who have already had about a year of immunotherapy. It compares two approaches: continuing the immunotherapy treatment versus stopping it. The main goal is to see if stopping treatment leads to similar survival rates while pot…

This study is testing whether giving two approved bladder cancer drugs less frequently can still control the disease while potentially reducing side effects. It involves 60 adults with advanced bladder cancer that has spread or cannot be surgically removed. The main goal is to se…

This study is testing a new combination of three drugs for advanced bladder cancer that has spread or cannot be surgically removed. The first part aims to find the safest and most effective doses. The second part will see how well the chosen dose combination works to shrink tumor…

This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…

This study is testing whether a combination of two drugs, pemetrexed and avelumab, can help control advanced bladder cancer that has spread and has a specific genetic feature (MTAP-deficient). The trial is for people whose cancer has worsened after prior treatment. Researchers wa…

This study is testing a new combination of two drugs, tazemetostat and pembrolizumab, for people with advanced bladder cancer that has spread or is resistant to standard chemotherapy. The main goals are to find the safest dose and see if the combination helps control the cancer b…

This was an early safety study for people with advanced bladder cancer that had spread. It aimed to test a combination of three drugs to see if they could control the cancer and were safe to use together. The study was withdrawn before any participants were enrolled.

This early-stage trial aims to find safe doses and understand side effects of several drug combinations for patients with advanced cancers that haven't responded to standard treatments. The study involves 155 participants with various advanced or metastatic cancers and some rare …

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study is testing an oral drug called sapanisertib for people with advanced bladder cancer that has a specific genetic mutation (TSC1 or TSC2) and has stopped responding to standard platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and control the …

This early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …

This early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug…

This study is for people with advanced bladder cancer that has spread and is no longer responding to standard immunotherapies. It compares a new two-drug chemotherapy combination (eribulin plus gemcitabine) against the doctor's usual choice of chemotherapy. The main goal is to se…

This study is testing a combination of three drugs—ipilimumab, nivolumab, and sacituzumab govitecan—as a first treatment for advanced bladder cancer that has spread. It is for patients who are not eligible for the standard chemotherapy drug cisplatin. The first part of the study …

This early-stage trial is testing the safety and initial effectiveness of combining two targeted cancer drugs for people with advanced bladder cancer that has spread or cannot be removed by surgery. The study will involve about 38 participants who have already received standard c…

This study is testing whether adding new experimental drugs to a standard two-drug treatment works better for people with advanced bladder cancer that has spread. It will involve about 390 participants who have not yet received treatment for their advanced cancer. The main goals …

This study is testing whether a blood test can more accurately identify patients with advanced bladder cancer who are eligible for a targeted drug called erdafitinib. Currently, doctors use a tissue sample from a past biopsy, which may not reflect the current state of the cancer.…